45 related articles for article (PubMed ID: 16821592)
1. Association between single nucleotide polymorphisms of drug resistance-associated genes and response to chemotherapy in advanced ovarian cancer.
Obata H; Yahata T; Quan J; Sekine M; Tanaka K
Anticancer Res; 2006; 26(3B):2227-32. PubMed ID: 16821592
[TBL] [Abstract][Full Text] [Related]
2. Genome-wide association study evaluating single-nucleotide polymorphisms and outcomes in patients with advanced stage serous ovarian or primary peritoneal cancer: An NRG Oncology/Gynecologic Oncology Group study.
Moore KN; Tritchler D; Kaufman KM; Lankes H; Quinn MCJ; ; Van Le L; Berchuck A; Backes FJ; Tewari KS; Lee RB; Kesterson JP; Wenham RM; Armstrong DK; Krivak TC; Bookman MA; Birrer MJ
Gynecol Oncol; 2017 Nov; 147(2):396-401. PubMed ID: 28935272
[TBL] [Abstract][Full Text] [Related]
3. Potential predictive markers of chemotherapy resistance in stage III ovarian serous carcinomas.
Osterberg L; Levan K; Partheen K; Delle U; Olsson B; Sundfeldt K; Horvath G
BMC Cancer; 2009 Oct; 9():368. PubMed ID: 19835627
[TBL] [Abstract][Full Text] [Related]
4. Prognostic implications of the nuclear localization of Y-box-binding protein-1 and CXCR4 expression in ovarian cancer: their correlation with activated Akt, LRP/MVP and P-glycoprotein expression.
Oda Y; Ohishi Y; Basaki Y; Kobayashi H; Hirakawa T; Wake N; Ono M; Nishio K; Kuwano M; Tsuneyoshi M
Cancer Sci; 2007 Jul; 98(7):1020-6. PubMed ID: 17459055
[TBL] [Abstract][Full Text] [Related]
5. A new DPYD genotyping assay for improving the safety of 5-fluorouracil therapy.
Sistonen J; Smith C; Fu YK; Largiadèr CR
Clin Chim Acta; 2012 Dec; 414():109-11. PubMed ID: 22935545
[TBL] [Abstract][Full Text] [Related]
6. Polymorphisms of
Fiszer-Maliszewska Ł; Łaczmański Ł; Dolińska A; Jagas M; Kołodziejska E; Jankowska M; Kuśnierczyk P
Anticancer Res; 2018 Mar; 38(3):1455-1459. PubMed ID: 29491071
[TBL] [Abstract][Full Text] [Related]
7. Integrative molecular profiling of routine clinical prostate cancer specimens.
Grasso CS; Cani AK; Hovelson DH; Quist MJ; Douville NJ; Yadati V; Amin AM; Nelson PS; Betz BL; Liu CJ; Knudsen KE; Cooney KA; Feng FY; McDaniel AS; Tomlins SA
Ann Oncol; 2015 Jun; 26(6):1110-1118. PubMed ID: 25735316
[TBL] [Abstract][Full Text] [Related]
8. Moving toward individualized therapy based on NER polymorphisms that predict platinum sensitivity in ovarian cancer patients.
Saldivar JS; Lu KH; Liang D; Gu J; Huang M; Vlastos AT; Follen M; Wu X
Gynecol Oncol; 2007 Oct; 107(1 Suppl 1):S223-9. PubMed ID: 17825393
[TBL] [Abstract][Full Text] [Related]
9. RVX-208, a BET-inhibitor for treating atherosclerotic cardiovascular disease, raises ApoA-I/HDL and represses pathways that contribute to cardiovascular disease.
Gilham D; Wasiak S; Tsujikawa LM; Halliday C; Norek K; Patel RG; Kulikowski E; Johansson J; Sweeney M; Wong NC; Gordon A; McLure K; Young P
Atherosclerosis; 2016 Apr; 247():48-57. PubMed ID: 26868508
[TBL] [Abstract][Full Text] [Related]
10. Whole-genome characterization of chemoresistant ovarian cancer.
Patch AM; Christie EL; Etemadmoghadam D; Garsed DW; George J; Fereday S; Nones K; Cowin P; Alsop K; Bailey PJ; Kassahn KS; Newell F; Quinn MC; Kazakoff S; Quek K; Wilhelm-Benartzi C; Curry E; Leong HS; ; Hamilton A; Mileshkin L; Au-Yeung G; Kennedy C; Hung J; Chiew YE; Harnett P; Friedlander M; Quinn M; Pyman J; Cordner S; O'Brien P; Leditschke J; Young G; Strachan K; Waring P; Azar W; Mitchell C; Traficante N; Hendley J; Thorne H; Shackleton M; Miller DK; Arnau GM; Tothill RW; Holloway TP; Semple T; Harliwong I; Nourse C; Nourbakhsh E; Manning S; Idrisoglu S; Bruxner TJ; Christ AN; Poudel B; Holmes O; Anderson M; Leonard C; Lonie A; Hall N; Wood S; Taylor DF; Xu Q; Fink JL; Waddell N; Drapkin R; Stronach E; Gabra H; Brown R; Jewell A; Nagaraj SH; Markham E; Wilson PJ; Ellul J; McNally O; Doyle MA; Vedururu R; Stewart C; Lengyel E; Pearson JV; Waddell N; deFazio A; Grimmond SM; Bowtell DD
Nature; 2015 May; 521(7553):489-94. PubMed ID: 26017449
[TBL] [Abstract][Full Text] [Related]
11. ABCA1 is associated with the development of acquired chemotherapy resistance and predicts poor ovarian cancer outcome.
Wang W; Lokman NA; Noye TM; Macpherson AM; Oehler MK; Ricciardelli C
Cancer Drug Resist; 2021; 4(2):485-502. PubMed ID: 35582032
[No Abstract] [Full Text] [Related]
12. Interaction Analysis of MRP1 with Anticancer Drugs Used in Ovarian Cancer: In Silico Approach.
Haque A; Baig GA; Alshawli AS; Sait KHW; Hafeez BB; Tripathi MK; Alghamdi BS; Mohammed Ali HSH; Rasool M
Life (Basel); 2022 Mar; 12(3):. PubMed ID: 35330134
[TBL] [Abstract][Full Text] [Related]
13. lncRNAs are novel biomarkers for differentiating between cisplatin-resistant and cisplatin-sensitive ovarian cancer.
Li Q; Zhang J; Zhou J; Yang B; Liu P; Cao L; Jing L; Liu H
Oncol Lett; 2018 Jun; 15(6):8363-8370. PubMed ID: 29805570
[TBL] [Abstract][Full Text] [Related]
14. The Role of Eukaryotic and Prokaryotic ABC Transporter Family in Failure of Chemotherapy.
El-Awady R; Saleh E; Hashim A; Soliman N; Dallah A; Elrasheed A; Elakraa G
Front Pharmacol; 2016; 7():535. PubMed ID: 28119610
[TBL] [Abstract][Full Text] [Related]
15. Prognostic Value and Implication for Chemotherapy Treatment of ABCB1 in Epithelial Ovarian Cancer: A Meta-Analysis.
Sun S; Cai J; Yang Q; Zhu Y; Zhao S; Wang Z
PLoS One; 2016; 11(11):e0166058. PubMed ID: 27812204
[TBL] [Abstract][Full Text] [Related]
16. Genetic variation of the ABC transporter gene ABCC1 (Multidrug resistance protein 1-MRP1) in the Polish population.
Słomka M; Sobalska-Kwapis M; Korycka-Machała M; Bartosz G; Dziadek J; Strapagiel D
BMC Genet; 2015 Sep; 16():114. PubMed ID: 26395522
[TBL] [Abstract][Full Text] [Related]
17. Paclitaxel sensitivity in relation to ABCB1 expression, efflux and single nucleotide polymorphisms in ovarian cancer.
Gao B; Russell A; Beesley J; Chen XQ; Healey S; Henderson M; Wong M; Emmanuel C; Galletta L; Johnatty SE; Bowtell D; ; Haber M; Norris M; Harnett P; Chenevix-Trench G; Balleine RL; deFazio A
Sci Rep; 2014 May; 4():4669. PubMed ID: 24810093
[TBL] [Abstract][Full Text] [Related]
18. The effects of ABCC2 G1249A polymorphism on the risk of resistance to antiepileptic drugs: a meta-analysis of the literature.
Chen P; Yan Q; Xu H; Lu A; Zhao P
Genet Test Mol Biomarkers; 2014 Feb; 18(2):106-11. PubMed ID: 24325761
[TBL] [Abstract][Full Text] [Related]
19. Nuclear multidrug-resistance related protein 1 contributes to multidrug-resistance of mucoepidermoid carcinoma mainly via regulating multidrug-resistance protein 1: a human mucoepidermoid carcinoma cells model and Spearman's rank correlation analysis.
Cai B; Miao Y; Liu Y; Xu X; Guan S; Wu J; Liu Y
PLoS One; 2013; 8(8):e69611. PubMed ID: 24013781
[TBL] [Abstract][Full Text] [Related]
20. Prognostic significance of several biomarkers in epithelial ovarian cancer: a meta-analysis of published studies.
Xu L; Cai J; Yang Q; Ding H; Wu L; Li T; Wang Z
J Cancer Res Clin Oncol; 2013 Aug; 139(8):1257-77. PubMed ID: 23595127
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
